France Vaccines Market Overview, 2028

Vaccines are of paramount importance in safeguarding public health and preventing the spread of infectious diseases. They represent one of the most effective and cost-efficient tools available to humanity for reducing illness, disability, and mortality caused by a wide range of pathogens. Vaccines work by stimulating the immune system to recognize and combat specific viruses or bacteria, creating immunity without causing the disease itself. This immunity not only protects the vaccinated individual but also contributes to herd immunity, reducing the overall prevalence of the disease in a community and protecting those who cannot be vaccinated, such as individuals with certain medical conditions or weakened immune systems. France is making global vaccine coverage a priority and remains determined to rally the international community in support of the countries hit hard by the pandemic. Some of the prominent vaccine brands in the French market include Sanofi Pasteur, a subsidiary of the global pharmaceutical giant Sanofi, which produces a range of vaccines, including those for influenza and pediatric diseases. Another key player is Pfizer, a multinational pharmaceutical company, known for its COVID-19 vaccine and other essential vaccines. Additionally, France is home to numerous domestic and international vaccine manufacturers, such as Seqirus, GlaxoSmithKline (GSK), and Merck, among others. These companies collaborate with the French government and health authorities to ensure a robust vaccination program, safeguarding public health in the country. The continuous development and distribution of vaccines by these brands and companies are crucial in preventing and managing various diseases in France. The French Ministry of Health plays a central role in the formulation of vaccination policies and strategies. It sets national vaccination guidelines, manages vaccine procurement, and coordinates vaccination campaigns. The Haute Autorité de Santé is France's High Health Authority, an independent public agency responsible for assessing the effectiveness, safety, and cost-effectiveness of vaccines and other medical interventions. HAS provides recommendations on vaccination schedules and guidelines for healthcare professionals. According to the research report, “France Vaccine Market Overview, 2028” published by Bonafide Research, the market is anticipated to add more than USD 900 Million from 2023 to 2028. In France, the usage of vaccines has played a pivotal role in expanding and nurturing the growth of the vaccine market over the years. The country has a long-standing commitment to public health and an established tradition of vaccination, with mandatory vaccination programs dating back to the 19th century. This commitment has translated into a robust healthcare infrastructure, a well-informed population, and a high level of trust in vaccines. One significant factor contributing to the growth of the vaccine market in France is the comprehensive and efficient vaccination programs implemented by the government. These programs encompass a wide range of vaccines, from childhood immunizations to those for adults and the elderly. France's commitment to public health is evident in the inclusion of new vaccines in its national immunization schedule, such as vaccines against pneumococcal diseases and human papillomavirus (HPV), which have expanded the market by addressing emerging health concerns. Furthermore, France's emphasis on healthcare infrastructure and public awareness campaigns has contributed to high vaccination coverage rates, creating a sustainable market for vaccines. The nation's healthcare professionals are well-trained and play a crucial role in administering vaccines, ensuring that the population receives the necessary immunizations.

Recombinant vaccines are usually produced by benefiting from bacteria, yeast, mammalian, and insect cells. This type of vaccine requires the insertion and transference of the DNA section responsible for encoding the antigen. Among the mentioned cells, bacterial expression is the most frequently utilized type that does not need modifications associated with mammalians’ and insects’ cells. Most of the recombinant vaccines developed in the recent decays are classified as recombinant protein vaccines. The downside of recombinant protein vaccines is their high cost and limited accessibility. Toxoid vaccines are a critical tool in preventing diseases caused by bacterial toxins. These vaccines are specifically designed to target and neutralize the harmful effects of toxins produced by certain bacteria rather than the bacteria themselves. By inactivating the toxins while preserving their antigenic properties, toxoid vaccines stimulate the immune system to produce antibodies that can recognize and neutralize the toxins. This immune response provides protection against diseases caused by the toxin-producing bacteria. Common examples of toxoid vaccines include those for diphtheria and tetanus. The diphtheria toxoid vaccine prevents the severe respiratory illness caused by the diphtheria toxin, while the tetanus toxoid vaccine protects individuals from the potentially fatal muscle rigidity and spasms induced by the tetanus toxin. Toxoid vaccines have proven highly effective in preventing these diseases and are often administered in combination with other vaccines in routine immunization schedules, ensuring individuals and communities are shielded from the debilitating effects of bacterial toxins. Based on the Route of Administration, the market is segmented into intramuscular and subcutaneous administration, Oral administrations, and Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.). Each vaccine has a recommended administration route and site. This information is included in the manufacturer’s package insert for each vaccine. Oral administration of vaccines is a method of delivering vaccines through the mouth, typically in the form of a liquid, tablet, or sugar cube. This route of vaccination offers several advantages and has been particularly useful in the global effort to immunize large populations, especially in developing countries. One key advantage of oral vaccines is their ease of administration. They do not require needles or syringes, which can reduce the fear and discomfort associated with vaccination. This makes oral vaccines particularly well-suited for vaccinating children, who may be more receptive to a less invasive method. Additionally, the absence of needles reduces the risk of needle injuries, making the vaccination process safer for healthcare workers. Oral vaccines are often used for diseases that primarily infect the gastrointestinal tract, such as polio and cholera. In recent years, advancements in vaccine technology have led to the development of more oral vaccines, including those against rotavirus, which causes severe diarrhea in infants and young children, and various enteric pathogens. These vaccines have contributed significantly to the reduction of morbidity and mortality from preventable diseases, particularly in regions with limited access to healthcare infrastructure. Rotavirus, adenovirus, cholera vaccine, and oral typhoid vaccines are the only vaccines administered orally. The market for vaccines is divided into two groups, pediatric vaccines and adult vaccines, according to the end-user of vaccines. The body uses immunity as a means of disease defense. Babies have a higher risk of contracting an infection and developing a serious illness because their immune systems have not fully matured by the time they are born. The use of childhood immunizations is substantially higher than that of adult vaccines. As part of standard immunization schedules, children often receive an extensive series of vaccinations from infancy through puberty. These schedules are carefully created to guard kids against a variety of diseases, such as measles, mumps, rubella, polio, and more. Because of the consistency of the pediatric vaccination schedules, there is a recurrently high demand for these vaccinations. Parental responsibility and understanding are crucial factors in the usage of pediatric vaccines. On the Basis of Disease Type, the number of usage of vaccines plays a vital role in the overall growth of the market. This is segmented into different type of disease including, Pneumococcal diseases, Cancer, Influenza, Rotavirus, Diphtheria, Pertussis, and Tetanus (DTP), Human, Papilloma Virus (HPV), Shingles, Meningococcal diseases, Hepatitis, Varicella (Chicken Pox), Mumps, and others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.). Pneumococcal infections can range from ear and sinus infections to pneumonia and bloodstream infections. Children at increased risk for pneumococcal disease include those younger than 2 years old. Adults 65 years or older are at increased risk for pneumococcal disease. As the France has a rapidly aging population, with a substantial proportion of elderly individuals. Older adults are particularly susceptible to pneumococcal infections due to age-related weakening of the immune system and often have underlying health conditions that increase their vulnerability. Young children in France are also at risk. This poses a risk to young children who may not have completed their vaccination schedules or have weaker immune systems. To address the high incidence rate of pneumococcal disease, France has implemented vaccination programs targeting both children and the elderly. Therefore, the utilization of pneumococcal vaccines holds the largest market share in 2022. Cancer remains a significant health concern worldwide, including in France. The burden of cancer is influenced by various factors, including an aging population and lifestyle factors such as smoking, poor diet, and lack of physical activity. In France, like in many other countries, efforts were being made to improve cancer prevention, early detection, and treatment options. The development and utilization of cancer vaccines are ongoing areas of research, and their market share may vary depending on factors such as the type of cancer, the effectiveness of the vaccines, and regulatory approvals. By the Type of Vaccines, the market is segmented into Multivalent and Monovalent Vaccines. To protect effectively, some vaccines require multiple antigens of one pathogen or different pathogen serotypes/serogroups in combination (multivalent or polyvalent vaccines). Multivalent vaccines and monovalent vaccines each hold distinct importance in the field of immunization, catering to different aspects of disease prevention. While multivalent vaccines are more commonly used in many vaccination programs, both types play crucial roles in safeguarding public health. Multivalent vaccines are designed to protect against multiple diseases or strains within a single vaccine shot. They offer the advantage of convenience, reducing the number of vaccinations individuals need to receive. Examples of widely used multivalent vaccines include those for measles, mumps, rubella (MMR), and the combination vaccines for various strains of influenza. These vaccines simplify vaccination schedules, improve compliance, and help control the spread of multiple diseases efficiently. On the other hand, monovalent vaccines are specifically tailored to protect against a single disease or pathogen. They are valuable when dealing with diseases where the pathogen exhibits significant variations, or when targeting a specific health threat, such as a new emerging infectious disease or a disease with a complex structure. Monovalent vaccines offer precision in immunization, ensuring focused protection against a particular threat. The choice between multivalent and monovalent vaccines depends on several factors, including the epidemiology of the disease, the population's susceptibility, and the availability of effective vaccines. Both types contribute to the success of vaccination programs and the reduction of disease burden. Multivalent vaccines provide broad protection, while monovalent vaccines offer tailored defense when needed. Based on the Distributional channels of vaccines, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Institutional Sales, and Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc). It is critical to keep each vaccine at its proper storage temperature like most vaccines (all inactivated vaccines and live nasal spray influenza vaccine) must be stored between 2° to 8°C (36° to 46°F), which is the recommended refrigerator temperature. Live varicella (chickenpox) and Zostavax (shingles) vaccines must be stored frozen between -50° to -15°C (-58° to +5°F). Vaccine storage standards in Germany were governed by regulations and guidelines set forth by the Paul-Ehrlich-Institute (PEI) and the Robert Koch Institute (RKI). Temperature monitoring devices, such as digital data loggers or thermometers, are used in vaccine storage units. Therefore such settings are highly maintained in the hospital pharmacies, thus its distribution from the hospital pharmacies holds the largest market share. A key improvement in public health is the expansion of vaccination availability in retail pharmacies. It improves accessibility, education, and convenience, which eventually results in higher vaccination rates and stronger community immunity against diseases that can be prevented. Given the growing importance of retail pharmacies in both healthcare delivery and public health activities, this trend is expected to continue.

Considered in this report: • Geography: France • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • France Vaccine Market with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Technology: • Conjugate vaccines • Inactivated & Subunit vaccines • Live Attenuated vaccines • Recombinant vaccines • Toxoid vaccines By Route of Administration: • Intramuscular and Subcutaneous Administration • Oral Administration • Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.) By End-User: • Paediatric Vaccines • Adult Vaccines By End-User: • Pneumococcal diseases • Cancer • Influenza • Rotavirus • Diphtheria, Pertussis, and Tetanus (DTP) • Human Papilloma Virus (HPV) • Shingles • Meningococcal diseases • Hepatitis • Varicella (Chicken Pox) • Mumps • Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.) By Type: • Multivalent vaccines • Monovalent vaccines By Distribution Channel: • Hospital Pharmacy • Retail Pharmacy • Institutional Sales • Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.) The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.